Inclusion Criteria:  Histopathologically proven prostate adenocarcinoma Age ≥ 18 years Patients already diagnosed with prostate cancer: Primary Staging: intermediate and high-risk patients per NCCN guidelines  Biochemical Recurrence: Rising PSA after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy):  a. Post radical prostatectomy (RP) - AUA recommendation i. PSA greater than or equal to 0.2 ng/mL measured more than 6-13 weeks after RP and confirmed by a second determination of a PSA level of >0.2 ng/mL b. Post-radiation therapy - ASTRO-Phoenix consensus definition i. Nadir + greater than or equal to 2 ng/mL rise in PSA  Ability to understand a written informed consent document, and the willingness to sign it.  Exclusion Criteria:  Unable to lie flat, still or tolerate a PET/CT scan, or any other condition that would preclude PET/CT imaging. Patients with any medical condition or circumstance that the investigator believes may compromise the data collection or lead to a failure to fulfil the study requirements. Patients with known hypersensitivity to the active substance or to any of the excipients of the investigational product.